CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Recruiting

Phase 1

CA-4948, FOLFOX, PD-1 Inhibitor, TrastuzumabCA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Sponsor:

Washington University School of Medicine

Code:

NCT05187182

Conditions

Gastric Cancer

Esophageal Cancer

Stomach Cancer

Esophagus Cancer

Gastroesophageal Junction Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CA-4948

Nivolumab

Pembrolizumab

Trastuzumab

mFOLFOX7

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by Washington University School of Medicine on 2025-01-15.